Is CTNM a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on The PROPEL-IPF readout for PIPE-791, with revenue (ttm) at ~$0 (no product or collaboration revenue reported in 2026). The bear case rests on the central risk is binary: if PROPEL-IPF does not show a meaningful FVC benefit, the stock has little to support it beyond cash, and that cash falls by roughly ~$60 million a year. Analysts covering it are spread from $14.00 to $30.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The central risk is binary: if PROPEL-IPF does not show a meaningful FVC benefit, the stock has little to support it beyond cash, and that cash falls by roughly ~$60 million a year. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $14.00, +97.7% from the $7.08 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

The PROPEL-IPF readout for PIPE-791. Nearly all of Contineum's value rests on this ~324-patient Phase 2 trial, which compares PIPE-791 with placebo on lung-function decline over 26 weeks. The most optimistic analyst target on CTNM is $30.00, +323.7% from the $7.08 price. That figure is only reachable if this thesis works close to its best case.

The central risk is binary: if PROPEL-IPF does not show a meaningful FVC benefit, the stock has little to support it beyond cash, and that cash falls by roughly ~$60 million a year. Even with positive data, admilparant is a Phase 3 asset backed by a large pharma company heading toward filings, so it would likely reach patients years before PIPE-791. The IPF market already includes Boehringer Ingelheim's Ofev (nintedanib), generic pirfenidone and Boehringer's newer nerandomilast, so a late entrant needs clear differentiation on efficacy, tolerability or convenience. PIPE-307 has now missed in two Phase 2 trials (multiple sclerosis in 2025 and depression in 2026), and J&J alone decides whether to continue, so the milestone stream could disappear. The research workforce cut and the departure of the chief scientific officer narrow the pipeline behind PIPE-791. The stock is small and highly sensitive to peer news, as the ~36% one-day fall on a competitor's trial showed, and any Phase 3 would almost certainly need new financing or a partner, which could dilute existing holders. The most pessimistic published target is $14.00, +97.7% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Clinical-stage San Diego biotech developing oral small molecules, led by PIPE-791 for idiopathic pulmonary fibrosis.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The PROPEL-IPF readout for PIPE-791) stalling in the reported numbers rather than in the narrative, the risk above (the central risk is binary: if PROPEL-IPF does not show a meaningful FVC benefit, the stock has little to support it beyond cash, and that cash falls by roughly ~$60 million a year) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Contineum is a San Diego clinical-stage biotech, formerly called Pipeline Therapeutics, that develops oral small-molecule drugs for fibrosis, inflammation and neurological disease. Its lead drug, PIPE-791, blocks the LPA1 receptor, which is involved in the scarring that destroys lung tissue in idiopathic pulmonary fibrosis. PIPE-791 is in PROPEL-IPF, a ~324-patient Phase 2 trial, and also completed an exploratory Phase 1b in chronic osteoarthritis and low back pain in April 2026. A second drug, PIPE-307, which targets the M1 muscarinic receptor, is licensed to Johnson & Johnson. The company has no approved products and no product sales, so its business today is running trials funded by the ~$236.6 million of cash and securities it held at June 30, 2026. It went public on the Nasdaq in April 2024 at $16 a share.

The move came from another company's trial. Bristol Myers Squibb reported topline Phase 3 ALOFT-IPF results for admilparant, a drug with the same LPA1 mechanism as PIPE-791. The 60 mg twice-daily dose met the primary endpoint, a statistically significant benefit on lung function at Week 52, but the 120 mg dose did not reach significance, and BMS did not disclose the size of the effect. CTNM closed the day at ~$8.57, down ~36% and near its 52-week low of ~$8.43. Investors appeared to weigh the dose-response question and the fact that a much larger rival is now heading toward regulatory filings, years ahead of PIPE-791, more heavily than the evidence that the mechanism can work. The stock had already dropped after the September PIPE-307 miss.

It cuts both ways. On the positive side, a Phase 3 success at 60 mg is the first large-scale evidence that blocking LPA1 can slow lung-function decline in IPF, and BMS described a favourable safety profile at both doses. That reduces the risk that the whole approach fails, which is the risk that matters most for a single-asset company. On the negative side, the 120 mg miss raises questions about how dose relates to benefit, which full data should help answer, and BMS now has a head start of several years toward approval, with the sales force and doctor relationships of a large pharma company. Contineum argues that PIPE-791's potency and once-daily dosing could set it apart. Whether that holds depends on PROPEL-IPF, which is estimated to complete in June 2028.